FDA TEST RESULTS

FDA Approval of the Odorox® MDU/Rx™ Device for Use in Medical Facilities

HGI INDUSTRIES INC.

A. Niger - Reduction in Viable Concentration vs. Time

Control + Triplicate MDU Decon Runs, Collison Nebulizer, AGI-30 Impinger Enumeration



E. herbicola - Reduction in Viable Concentration vs. Time

Control + Triplicate MDU Decon Runs, Collison Nebulizer, AGI-30 Impinger Enumeration



MS2 - Reduction in Viable Concentration vs. Time

Control + Triplicate MDU Decon Runs, Collison Nebulizer, AGI-30 Impinger Enumeration



PhiX174 - Reduction in Viable Concentration vs. Time

Control + Triplicate MDU Decon Runs, Collison Nebulizer, AGI-30 Impinger Enumeration



Staphylococcus epidermidis - Reduction in Viable Concentration vs. Time

Control + Triplicate MDU Decon Runs, Collison Nebulizer, AGI-30 Impinger Enumerationin Triplicate



Summary MDU/Rx™ Log Reduction Over Control

Large Chamber, Average +/- ST. Dev Log Reduction, Triplicate MDU/Rx Trials